Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition.

These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.

Inclusion Criteria:

• Patient is at least 18 years of age
• Diagnosis of recurrent prostate cancer
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Enrolled in another research study
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Inability to provide written informed consent

Patients with recurrent prostate cancer who are actively considering enrolling in a clinical study, but have not yet completed enrollment and randomization.